NASDAQ, RPRX - Royalty Pharma Plc Cl A
Repros Therapeutics Inc. (?the Company?, ?RPRX,? or ?we,? ?us? or ?our?),
was organized on August 28, 1987. We are a development stage biopharmaceutical
company focused on the development of oral small molecule drugs for major unmet
medical needs. We have a proven track-record of efficient and rapid advancement
of our therapeutic candidates through clinical development.
Our current product pipeline includes:
Proellex
? Phase 3 for the treatment of anemia associated with uterine fibroids
? Phase 3 for the chronic treatment of uterine fibroids
? Phase 2 for the treatment of endometriosis
Androxal
? Planned Phase 2b trial to treat men with AIHH, with concomitant plasma
glucose and lipid elevations
? Planned Phase 2b trial in men with low testosterone levels wanting to
improve or maintain their fertility a ...
Read SEC Filing on NASDAQ.com »